Clinical trial
Efficacy and Safety Evaluation of Pegamotecan (PEG-camptothecin) in Advanced or…
NCT00079950 · Enzon Pharmaceuticals, Inc., Industry · Suspended
Key facts
| NCT number | NCT00079950 |
|---|---|
| Title | Efficacy and Safety Evaluation of Pegamotecan (PEG-camptothecin) in Advanced or Metastatic Soft Tissue Sarcoma |
| Lead sponsor | Enzon Pharmaceuticals, Inc., Industry |
| Status | Suspended |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Sarcoma, Soft Tissue |
| Intervention type | Drug |
| Interventions | Pegamotecan |
| Start date | Aug 1, 2003 |
| First posted | Mar 22, 2004 |
| Last update posted | Sep 6, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: